• Toremifene Citrate: Clinical Pharmacology and Research

  2026-09-02

  The reference paper presents toremifene citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator, integrating mechanism, clinical positioning, pharmacokinetics, safety monitoring, and nursing considerations. Its practical value lies in showing how receptor biology, comparative evidence with tamoxifen, metabolism, drug interactions, and patient selection should shape breast cancer research and translational study design.

• Realgar Neurotoxicity and the Liver–Brain Ornithine Axis

  2026-09-02

  A 2025 Advanced Science study identifies a liver–brain mechanism in which realgar-derived arsenic inhibits hepatic OTC, elevates ornithine, and promotes ZBTB7A-dependent suppression of astrocyte glycolysis. The findings connect disrupted urea cycle metabolism with frontal-lobe energy failure and behavioral deficits, while offering a framework for studying ornithine-dependent neurotoxicity.

• CX-4945 (Silmitasertib): CK2 Research Guide

  2026-09-01

  CX-4945, also called Silmitasertib, is a selective ATP-competitive CK2 inhibitor used to study PI3K/Akt signaling, apoptosis, and context-dependent cell-cycle control. Product data and a 2026 ischemic-stroke study support CX-4945 as a mechanistic CK2 probe, but they do not establish a universal anticancer or clinical treatment effect.

• Ac-YVAD-CMK for Membrane-Inflammation Dissection

  2026-09-01

  Ac-YVAD-CMK enables mechanistic separation of caspase-1-driven inflammation from plasma-membrane repair in Kupffer cell and Listeria models. This article translates TMEM16F research into a decision framework for interpreting cytokines, pyroptosis, and liver injury data.

• AZD2461: A Novel PARP Inhibitor Workflow

  2026-08-31

  AZD2461 is a novel PARP inhibitor for connecting PARP-1 suppression with DNA damage response, cell-cycle arrest, and cancer-cell killing. A paired viability-and-death workflow helps distinguish true cytotoxicity from reversible growth inhibition while testing resistance biology in breast cancer models.

• DON Liver Injury: Mitophagy and Nrf2 Signaling

  2026-08-31

  This study proposes that deoxynivalenol-induced liver injury is driven by excessive PINK1/Parkin-mediated mitophagy together with suppression of the p62–Keap1–Nrf2 cytoprotective pathway. Mouse and AML-12 cell experiments, including pathway inhibition and p62 rescue, provide a mechanistic framework for interpreting mitochondrial damage, oxidative stress, inflammation, apoptosis, and lipid metabolic disruption.

• AZD2461: A Better Way to Read PARP Responses

  2026-08-30

  AZD2461 is a novel PARP inhibitor for dissecting DNA repair pathway modulation, drug resistance, and response kinetics in breast cancer models. This guide pairs its mechanistic profile with a rigorous framework for separating growth inhibition from true cell killing in vitro.

• VX-661: F508del CFTR Corrector Workflow

  2026-08-29

  Build more interpretable cystic fibrosis research assays with VX-661 by separating CFTR trafficking rescue from channel potentiation. This workflow combines practical dosing, orthogonal surface-expression and function readouts, and calnexin-aware controls for variant-specific optimization.

• Vincristine sulfate: Reliable Cell Assay Workflows

  2026-08-28

  Learn how Vincristine sulfate (SKU A1765) supports reproducible viability, proliferation, and cytotoxicity experiments through a defined microtubule-disruption mechanism and practical solubility guidance. This scenario-based guide covers assay design, dose selection, data interpretation, and product evaluation for cancer research.

• Phage-Layer Interferometry for Phage Diagnostics

  2026-08-28

  The reference study introduces phage-layer interferometry (PLI) as a quantitative companion diagnostic for selecting therapeutic phages and as a prototype platform for bacterial detection. Its key practical advance is real-time, automatable analysis that remains usable in complex opaque matrices, where conventional optical assays are difficult to interpret.

• CCT007093: PPM1D Inhibitor Workflow

  2026-08-27

  CCT007093 is a practical chemical probe for connecting PPM1D inhibition with p38 signaling, viability loss, and inflammatory cell-death phenotypes. This workflow shows how to move from solvent and dose controls to mechanistic rescue experiments in breast cancer and renal tubular models.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-08-27

  This reagent provides HRP-mediated detection of rabbit primary IgG in Western blot, ELISA, IHC, and IC workflows. It should be used as a research secondary antibody with assay-specific optimization, not as a diagnostic reagent or as evidence of performance beyond the supplied product dossier.

• Bradykinin: Practical Assay Handling Guide

  2026-08-26

  Bradykinin (SKU BA5201) provides a defined peptide perturbation for vascular reactivity, permeability, smooth muscle, pain, and inflammation experiments. This guide covers storage, solution handling, controls, and troubleshooting; the material is for scientific research only and should not be used for diagnosis, treatment, or direct medical application.

• Catalpol, Glycolysis, and EphA2 in Liver Fibrosis

  2026-08-26

  The reference study identifies a mechanistic link between catalpol, aerobic glycolysis, and EphA2/FAK/Src signaling in hepatic stellate cells. Using complementary mouse and cell models, it shows that catalpol reduces stellate-cell activation, inflammation, and fibrotic remodeling, while highlighting EphA2 as a potential metabolic control point.

• Biotin-XX Tyramide Reagent in Spatial Proteomics

  2026-08-25

  Biotin-XX Tyramide Reagent combines HRP-driven amplification with membrane exclusion for selective cell-surface detection in tissue sections. This guide translates its chemistry into practical IHC, ISH, multiplex imaging, and proximity-proteomics workflows, with starting parameters and troubleshooting advice.

7799 records 1/520 page Next 12345 下5页 Last page